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Abstract: 30 
Antiviral CD8+ T cells are a key component of the adaptive immune response against HCV, but 31 
their impact on viral control is influenced by pre-existing viral variants in important target 32 
epitopes and the development of viral escape mutations. Immunodominant epitopes highly 33 
conserved across genotypes therefore are attractive for T cell based prophylactic vaccines. Here, 34 
we characterized the CD8+ T cell response against the highly conserved HLA-B*51-restricted 35 
epitope IPFYGKAI1373-1380 located in the helicase domain of NS3 in people who inject drugs 36 
(PWID) exposed predominantly to HCV genotypes 1a and 3a. Despite this epitope being 37 
conserved in both genotypes, the corresponding CD8+ T cell response was detected only in PWID 38 
infected with genotype 3a and HCV-RNA negative PWID, but not in PWID infected with 39 
genotype 1a. In genotype 3a, detection of strong CD8+ T cell responses was associated with 40 
epitope variants in the autologous virus consistent with immune escape. Analysis of viral 41 
sequences from multiple cohorts confirmed HLA-B*51-associated escape mutations inside the 42 
epitope in genotype 3a, but not in genotype 1a. Here, a distinct substitution in the N-terminal 43 
flanking region located 5 residues up-stream of the epitope (S1368P; p=0.00002) was selected in 44 
HLA-B*51-positive individuals. Functional assays revealed that the S1368P substitution 45 
impaired recognition of target cells presenting the endogenously processed epitope. The results 46 
highlight that, despite an epitope being highly conserved between two genotypes, there are major 47 
differences in the selected viral escape pathways and the corresponding T cell responses. 48 
Importance: HCV is able to evolutionary adapt to CD8+ T cell immune pressure in multiple 49 
ways. Beyond selection of mutations inside targeted epitopes this study demonstrates that HCV 50 
inhibits epitope processing by modification of the epitope flanking region under T cell immune 51 
pressure. Selection of a substitution five amino acids upstream of the epitope underlines that 52 
efficient antigen presentation strongly depends on its larger sequence context and that blocking of 53 
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the multi-step process of antigen processing by mutation is exploited also by HCV. The pathways 54 
to mutational escape of HCV are to some extent predictable but are distinct in different 55 
genotypes. Importantly, the selected escape pathway of HCV may have consequences for the 56 
destiny of antigen-specific CD8+ T cells.57 
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Introduction: 58 
Based on phylogenetic analysis HCV can be classified into at least seven genotypes and multiple 59 
subtypes that differ up to 20% at the amino acid level (1). The HCV genotypes have distinct 60 
epidemiological characteristics, are associated with different transmission risk factors and their 61 
frequencies in a population are regionally different. In Europe and North America the HCV 62 
genotypes 1 and 3 are most common (2, 3). Since routine screening via nucleic acid amplification 63 
for HCV eliminated the risk for infection through blood products, the most important risk group 64 
for incident HCV infection are people who inject drugs (PWID). The high prevalence of HCV 65 
infection with seroprevalence rates up to 80% paired with frequent risk practices for HCV 66 
transmissions in PWID results in incidence rates between 8% and 25% per year in young adult 67 
injectors (4, 5) and there is strong evidence that multiple exposures are common in this risk group 68 
(6, 7). The degree of sequence diversity between genotypes and subtypes precludes broad 69 
protection against re-infection. Accordingly, multiple infections of the same individual with 70 
different viruses have been reported (7). 71 
 72 
Even at the subtype level HCV isolates typically differ between hosts. Lack of a proof reading 73 
function of the virus encoded RNA-dependent RNA polymerase results in a high error rate during 74 
RNA replication. As a consequence, HCV exists in chronically infected patients as a quasispecies 75 
of closely related but genetically distinct viral variants. There is now strong evidence that viral 76 
genetic variation between hosts is the product of continuous selection of mutations by host 77 
immune pressure (8-14). Collectively, this inherent sequence diversity of HCV at the genotype, 78 
subtype and quasispecies level is a major obstacle to vaccine design (15). Strategies that aim to 79 
develop prophylactic vaccines against HCV have to cope with this genetic heterogeneity either by 80 
inducing immune responses with a high degree of cross-reactivity (16, 17), by inducing multiple 81 
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responses against different sequence variants (18) or by focussing the immune response on highly 82 
conserved regions of the virus.  83 
 84 
Dominant CD8+ T cell epitopes that are conserved across different HCV genotypes are rare (19, 85 
20). Here, we characterized a highly conserved dominant HLA-B*51-restricted CD8+ T cell 86 
epitope (IPFYGKAI1373-1380) in HCV NS3 in PWID predominantly exposed to genotype 1a and 87 
3a. Vigorous responses were detected in PWID with spontaneous immune control of HCV and in 88 
PWID with genotype 3a infection, but not in PWID infected with genotype 1a. Although 89 
selection of mutations inside the epitope was overall rare, there was evidence for mutational 90 
escape in HCV genotype 1b and 3a by population sequence analysis. Interestingly, HCV 91 
genotype 1a followed a distinct escape pathway by selecting a substitution (S1368P) located five 92 
amino acids up-stream of the epitope. Further analysis of the functional relevance revealed that 93 
the S1368P substitution altered epitope processing. The results demonstrate that beyond selection 94 
of mutations inside CD8+ epitopes HCV adapts to immune pressure by selecting mutations in the 95 
epitope flanking region. The evolutionary escape pathways differ between HCV genotypes 96 
indicating distinct genetic plasticity. 97 
 98 
Methods: 99 
Patients 100 
Blood samples from patients with a history of injection drug use were collected from the ward for 101 
inpatient detoxification treatment of drug addicts or the clinic for opioid maintenance treatment 102 
(OMT) at the Department of Addictive Behaviour and Addiction Medicine, Rhine State Hospital 103 
Essen, Hospital of the University of Duisburg-Essen. Written informed consent was obtained 104 
from all study participants and the study was approved by the ethics committee of the Medical 105 
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Faculty of the University of Duisburg-Essen in accordance with the Declaration of Helsinki. In 106 
total 43 HLA-B*51 positive treatment-naïve subjects who were HCV antibody positive (by anti-107 
HCV CMIA from Abbott) were analyzed, including 15 HCV-RNA negative patients and 28 108 
subjects with detectable HCV-RNA. Peripheral blood mononuclear cells (PBMCs) were isolated 109 
from blood via Ficoll gradient centrifugation and subsequently cryopreserved.  110 
 111 
Analysis and Alignment of HCV Sequences 112 
The frequency of HLA-B*51-associated sequence polymorphisms was analyzed in 405 HCV 113 
genotype 1a sequences and 145 HCV genotype 1b sequences from a multi-center cohort (21) and 114 
in a large HCV genotype 1b outbreak (22). A region covering the epitope IPFYGKAI1373-1380 was 115 
amplified and sequenced from additional 37 HCV genotype 1a isolates as well as 102 HCV 116 
genotype 3a isolates collected in Germany. All sequences have been submitted to GenBank 117 
(accession no. FJ864775-864816, KJ130249-130317 and KJ668232-KJ668268).  118 
 119 
Analysis of the CD8+ T Cell Response 120 
Antigen-specific T cells were expanded from cryopreserved HLA-B*51 positive PBMCs 121 
utilizing synthetic peptides (>70% purity) purchased from EMC, Tübingen, Germany. After 122 
thawing PBMCs were cultured in RPMI 1640 medium containing 10% fetal calf serum, 100 123 
U/ml penicillin, 100µg/ml streptomycin, 10 mM HEPES buffer and 25 U/ml recombinant 124 
interleukin-2 (IL-2) and stimulated with the HLA-B*51 peptide 1373 (1 µg/ml per peptide) and 125 
0.1 µg/ml anti-CD28 and anti-CD49d. After 7 days medium containing IL-2 was added. On day 126 
10 the cells were restimulated with the same peptide (10 µg/ml) in the presence of Brefeldin A 127 
(100 ng/ml) for 4 h and then analysed for their CD4+, CD8+ and IFN-γ expression via flow 128 
cytometry. To determine the degree of cross-reactivity between different B*51-1373 variants, 129 
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PBMCs were cultivated in the presence of the HLA-B*51-1373 prototype or the variant peptide. 130 
After 10 days, both cultures were restimulated with the prototype and the variant peptide at 131 
different concentrations before intracellular IFN-γ staining. For detection of HCV-specific cells 132 
ex vivo and after peptide-specific in vitro expansion, thawed PBMCs were stained with PE-133 
labeled IPFYGKAI-specific HLA-B*5101 dextramer (Immudex, Denmark) followed by surface 134 
staining with CD8+ PerCP-Cy5.5 (eBioscience). All samples were acquired using a FACS Canto 135 
(BD) and the data was analyzed using FlowJo software (Tree Star Inc.)  136 
 137 
Expression plasmids for HCV-GFP fusion proteins 138 
All constructs were based on the parental plasmids pEGFP-N1 (Clontech, Germany) featuring a 139 
CMV promoter controlled eGFP protein for N-terminal fusion. Fragments of NS3 were generated 140 
by amplifying NS3 1329-1433 by nested PCR with primers 4b-F 141 
(CCTACGGCAAGTTCCTTGC) and 4b-R_new (GCAGTCTATCACCGAGTCG) and B51-for-142 
EcoRI (ccaagggaattcttggcttcgtcttcaccctcggcatcggcacygtccttgaccaag) and B51-Rev-SalI 143 
(cggataccgtcgacccgcggtartamgccacggc). Subsequently the fragment was cloned via EcoRI/SalI 144 
into pEGFP-N1. The substitution S1368P was introduced via site directed mutagenesis 145 
(Stratagene) using primer B51-S1368P-for (ggaggttgctctgcccaccaccggaga) and B51-S1368P-rev 146 
(tctccggtggtgggcagagcaacctcc) according to the manufacturer’s instructions. All constructs were 147 
verified by DNA sequencing. 148 
 149 
Analysis of the CD8+ T cell response against endogenously processed antigens 150 
HLA-B*51 PBMCs from healthy donors were obtained from buffy coats (Department of 151 
Transfusion Medicine, Essen). For analysis of endogenously processed antigens, HLA-B*51 152 
positive cells were electroporated with plasmids pac-NS3-S1368S-GFP or pac-NS3-S1368P-GFP 153 
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encoding a NS3-GFP fusion protein utilizing the Amaxa T cell nucleofector kit (vpa-1002; 154 
Lonza). In brief, after thawing PBMCs were cultured in RPMI medium. After 24 h 7x106 cells 155 
were re-suspended in 100 µl Nucleofector™ Solution , mixed with 7.5 µg DNA and pulsed with 156 
the Optimized Protocol for Unstimulated Human T Cells (Program v024, Amaxa2b) with an 157 
Amaxa apparatus (Lonza). After electroporation PBMCs were cultured in RPMI medium for 24 h 158 
cells before GFP positive cells were sorted using a FACSAria II (BD). Subsequently, 1x105 159 
B*51-1373 specific cells from a 10 day culture were restimulated with GFP positive cells in a 1:1 160 
ratio for 4 h before intracellular IFN-γ staining. 161 
 162 
In vitro proteasome digestion 163 
The synthetic peptides EVALSTTGEIPFYGKAIPLEAIKGG and 164 
EVALPTTGEIPFYGKAIPLEAIKGG (≥ 95% purity) were purchased from EMC, Tübingen, 165 
Germany and digested using the 20S proteasome assay kit complemented with human 166 
constitutive or immunoproteasome (Boston Biochem). In brief, 20 µg of peptide were digested 167 
with 4 µg of SDS-activated proteasome in a 500 µl reaction. The reaction was stopped on 168 
indicated time points by adding 3 volumes of ice-cold acetone. For precipitation of proteasome 169 
the samples were subsequently frozen at -20°C for 30 min and then centrifuged for 30 min at 4°C 170 
with 15000 rpm. Supernatants were collected, evaporated to dryness and dissolved in 50 µl 0.1 % 171 
trifluoroacetic acid. The peptide concentration of the resulting solution was determined by amino 172 
acid analysis as previously described (23). For the subsequent LC-MS/MS experiment, the 173 
sample was diluted to a concentration of 0.33 pmol/µl and 5 pmol were analyzed using an 174 
Ultimate 3000 RSLCnano system online coupled to a Velos Pro linear ion trap mass spectrometer 175 
(both Thermo Scientific, Bremen, Germany) as described earlier (23). The acquired raw files 176 
were further analyzed with Proteome Discoverer software (Thermo Scientific, ver. 1.3.0.339) and 177 
  Genotype-dependent Immune Escape of HCV 
 9
searched with Sequest (24) against a self-written database containing the investigated pt and 178 
S1368P peptides. Precursor and fragment ion mass tolerance was set to 0.4 Da and the 179 
confidence level of peptide identification was set to a false discovery rate of 1 %. Relative 180 
peptide quantification was carried out via spectral counting. Thereto a normalized spectral index 181 
was calculated for each of the identified peptides by dividing the number of acquired peptide 182 
spectrum matches (PSMs) of a particular peptide by the number of PSMs acquired in the whole 183 
sample. 184 
 185 
Generation and analysis of TNcc viruses.  186 
Plasmid pTNcc encoding for the GT1a virus TNcc was kindly provided by Jens Bukh (25). 187 
Mutations S1368P, I1373V and I1380L were introduced by site directed mutagenesis and all 188 
constructs were verified by DNA sequencing. In vitro transcription and electroporation of Huh-189 
7.5 cells was performed as described before (26). 4 h post transfection medium was changed with 190 
fresh DMEM (2 mM l-glutamine, nonessential amino acids, 100 U/ml of penicillin, 100 μg/ml of 191 
streptomycin, and 10 % fetal calf serum) supplemented with or without 10 mM 2´CMA (kindly 192 
provide by T. Tellinghuisen,(27)). 72 h post transfection, cell-free supernatant was filtered 193 
through 0.45 µM filters and 10x concentrated through Amicon centrifugal filters (Millipore). 194 
Virus titers were determined as described elsewhere (28) with slight modifications. In brief, Huh-195 
7.5 cells were seeded in 96-well plates at a density of 1 × 104 cells per well 24 h prior to 196 
inoculation with dilutions of filtered cell culture supernatant (at least six wells were used per 197 
dilution). After 3 days, cells were washed with PBS, fixed for 20 min with ice-cold methanol at 198 
−20°C, washed three times with PBS. HCV infected cells were detected with anti-core C7.50 199 
(1:300) (29) and anti-NS5A 9E10 (1:1000) (28) antibody in PBS for 45 min at room temperature. 200 
Cells were washed as described above, and bound antibodies were detected by incubation with 201 
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horseradish peroxidase-conjugated antibodies specific to murine IgG (Sigma-Aldrich, Steinheim, 202 
Germany) diluted 1:200 in PBS. After 1 h incubation at room temperature, cells were washed as 203 
specified above. Peroxidase activity was detected by using Carbazole substrate (0.32% (w/v) of 204 
3-amino-9-ethylcarazole (Sigma) in N,N-dimethyl-formamide was diluted at a ratio of 1:3.3 with 205 
15 mM acetic acid, 35 mM sodium acetate, pH 8.0, and 0.4% H2O2.). Virus titers (50% tissue 206 
culture infective dose [TCID50/ml]) were calculated based on the method of Spearman and 207 
Kärber. HCV RNA was quantified by X-tail reverse transcriptase (RT)-PCR as described before 208 
(22). For detection of HCV core protein virus containing supernatant was inactivated by addition 209 
of Triton X-100 to a final concentration of 1% (v/v) and the amount of released core protein was 210 
determined by the commercially available core ELISA ARCHITECT HCV core AG test (Abbott, 211 
Wiesbaden, Germany). 212 
 213 
Statistical Analysis.  214 
All statistical tests were performed using GraphPad Prism 5.0 software (GraphPad Software, San 215 
Diego, CA).  216 
 217 
 218 
  219 
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Results 220 
CD8+ T cells directed against the epitope IPFYGKAI1373-1380 are detected after spontaneous 221 
resolution and in chronic genotype 3a infection but not in chronic genotype 1a infection 222 
We previously reported an HLA-B*51-restricted epitope in NS3 (IPFYGKAI1373-1380) that is 223 
>90% conserved across the HCV genotypes 1a, 1b and 3a (19). The CD8+ T cell immune 224 
response directed against the epitope IPFYGKAI1373-1380 was analyzed in a cohort of anti-HCV 225 
positive PWID carrying the HLA-B*51 allele. A total of 43 subjects were analyzed, including 15 226 
anti-HCV positive PWID with undetectable HCV-RNA, 13 PWID infected with GT1a, 3 PWID 227 
infected with GT1b and 12 PWID infected with GT3a. After 10 days of in vitro expansion 228 
IPFYGKAI-specific CD8+ T cells were detectable in 12 out of 15 (80%) individuals with 229 
undetectable viremia and in 6 out of 12 (50%) patients chronically infected with genotype 3a 230 
(figure 1A). In contrast, CD8+ T cells directed against this epitope were not detectable after 231 
antigen-specific expansion in patients with genotype 1a or 1b infection (figure 1A). Similar 232 
results were obtained when CD8+ T cell were directly analyzed ex vivo with HLA class I/peptide-233 
dextramers. IPFYGKAI-specific CD8+ T cells were detectable in most HCV-RNA negative 234 
PWID and some PWID with genotype 3a infection. Notably, the four genotype 3a-infected 235 
patients with high frequencies were identical to those where antigen-specific CD8+ T cells were 236 
efficiently expanded in vitro (figure 1A). In turn, the analysis with HLA class I/peptide 237 
dextramers confirmed lack of detection of IPFYGKAI-specific CD8+ T cells in patients infected 238 
with genotype 1 (figure 1B). The CD8+ T cell response against the epitope IPFYGKAI1373-1380 239 
was also studied in a patient with acute HCV genotype 1a infection. The patient was previously 240 
reported in a study on the impact of HLA-B*57 on HCV infection outcome (30) and was also 241 
HLA-B*51 positive. Interestingly, here, the response was detectable by week 11 after infection 242 
but became completely undetectable in an IFN-γ ELISpot by week 47 (figure 1C).  243 
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 244 
The autologous virus of 22 PWID from the total of 26 with detectable HCV-RNA was 245 
sequenced. The sequences of the epitope and the flanking region are shown in table 1 and are 246 
indicated in figure 1A for PWID with genotype 3a infection with a detectable CD8+ T cell 247 
response (colored in figure 1A). In three of ten HCV genotype 3a sequences the virus harbored 248 
substitutions in the epitope region (I1373V, K1377R or I1380L). Of note, all three patients 249 
mounted robust responses against the prototype sequence (figure 1A). In functional assays the 250 
I1380L variant impaired recognition by antigen-specific CD8+ T cells whereas the I1373V 251 
variant was cross-reactive in HCV-RNA negative PWIDs and to a lesser extent in GT3a infected 252 
PWIDs (figure 1D and E). Notably, the three remaining GT3a-infected patients with detectable 253 
CD8+ T cell responses and no evidence for escape mutations had a history of injection drug use 254 
of less than 6 months consistent with more recent exposure and infection with HCV possibly at a 255 
stage prior to mutational escape. One of nine GT1a sequences and one of three GT1b sequences 256 
harbored the I1373V substitution in position 1 of the epitope. In both patients no CD8+ T cell 257 
response was detectable. One PWID with genotype 1a infection harbored a S1368P substitution. 258 
Notably, this substitution was also selected in the patient with acute HCV genotype 1a infection 259 
and with the rapid decline of the CD8+ T cell response (figure 1C and data not shown). 260 
 261 
The residue under selection pressure in HLA-B*51-positive individuals depends on the viral 262 
genotype  263 
Given the relatively high reproducibility of IPFYGKAI-specific CD8+ T cell responses in HCV-264 
RNA negative PWID we aimed to address if there is evidence for immune escape in patients with 265 
persistent HCV infection at a population level. We therefore analyzed the impact of HLA-B*51-266 
expression on the frequency of sequence polymorphisms in this epitope in different cohorts. In an 267 
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analysis of 442 genotype 1a sequences from a multi-center cohort (figure 2A) there was no 268 
evidence for mutational escape inside the epitope. Although an I1373V polymorphism was 269 
observed, this substitution was not enriched in HLA-B*51-positive patients. In contrast, the 270 
I1373V polymorphism was slightly enriched in HLA-B*51-positive patients from a multi-center 271 
cohort of 145 genotype 1b infected patients (figure 2B), although this difference was not 272 
statistically significant. However, in a large genotype 1b single source outbreak there was 273 
statistical evidence for selection of polymorphisms in position 1 (I1373V) and 8 (I1380L) of the 274 
epitope in the presence of HLA-B*51 (figure 2C). Finally, we also analyzed a local cohort of 102 275 
patients infected with genotype 3a (figure 2D). Here, there was statistical evidence for selection 276 
of the I1373V polymorphism inside the epitope. Importantly, even though in genotype 1a there 277 
was no evidence for mutational escape inside the epitope, there was strong statistical evidence for 278 
HLA-B*51-associated selection pressure on a residue located five amino acids up-stream of the 279 
epitope (S1368) (figure 2A). In genotype 1a 20.7% of the HLA-B*51-positive patients carried a 280 
S1368P substitution, in contrast, only 0.8% of the HLA-B*51-negative patients carried any 281 
substitutions in this position (p=0.00002). Notably, in genotype 3a an S1369P substitution was 282 
also enriched in HLA-B*51-positive individuals, however, the difference was not statistically 283 
significant (figure 2D). Taken together, by analyses of different cohorts we found statistical  284 
evidence for mutational escape inside the HLA-B*51-restricted epitope (IPFYGKAI) in genotype 285 
1b and 3a and evidence for selection of a distinct substitution in the epitope flanking region in 286 
genotype 1a. 287 
 288 
The S1368P substitution impairs targeting of the endogenously processed HLA-B*51 restricted 289 
epitope IPFYGKAI1373-1380 290 
HCV genotype 1a was unique because evidence for HLA-B*51-associated selection pressure was 291 
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only observed in the epitope flanking region. Of note, this region does not contain a second HLA-292 
B*51 binding motif by analysis with prediction algorithms for HLA class I-binding 293 
(www.immuneepitope.org). We therefore hypothesized that the S1368P may impair processing 294 
and presentation of the epitope. To address this experimentally, an assay that allows analysis of 295 
endogenously processed antigens was established. Effector CD8+ T cells directed against the 296 
HLA-B*51-restricted epitope IPFYGKAI were obtained by 10 days of antigen-specific 297 
expansion from different PWID with spontaneous immune control of HCV. To generate target 298 
cells that present the endogenously processed epitope HLA-B*51 positive buffy coat cells were 299 
transfected with expression plasmids encoding a fusion protein of a short fragment of NS3 300 
containing the epitope fused to GFP. 24h after transfection GFP-positive cells were sorted and 301 
used as targets for specific CD8+ T. As a positive control native target cells were pulsed with the 302 
synthetic peptide overnight. Figure 3A shows a representative result of one experiment. Upon 303 
stimulation with peptide-pulsed targets 6.3% IFN-γ+ CD8+ T cells were detectable. When targets 304 
were transfected with a genotype 1a prototype sequence 7.3% of CD8+ T cells secreted IFN-γ. In 305 
contrast, when targets were transfected with the plasmid harboring the S1368P substitution the 306 
number of IFN-γ+CD8+ T cells was reduced to 1.3%. In seven independent experiments the CD8+ 307 
T cell response against targets transfected with the S1368P-variant was reproducibly reduced to 308 
levels of 24% compared to prototype 1a (figure 3B). This suggests that less antigen was 309 
presented on S1368P-transfected target cells consistent with impaired endogenous processing 310 
associated with this substitution. To compare the processing efficiency between genotype 1a and 311 
genotype 3a the same fusion proteins were constructed with the 3a prototype sequence and the 312 
genotype 3a S1369P substitution. In three independent experiments the CD8+ T cell response 313 
against targets transfected with prototype 3a were reproducibly weaker (33%) compared to 314 
prototype 1a. The S1369P substitution further reduced the response to 6% compared to prototype 315 
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1a. This suggests that the epitope is less efficiently processed in a genotype 3a context compared 316 
to a genotype 1a context. Moreover, both substitutions in the epitope flanking region (S1368P in 317 
genotype 1a and S1369P in genotype 3a) further reduce the antigen processing efficiency.    318 
 319 
Differential proteasomal cleavage of peptides with the S1368P substitution 320 
It was next addressed if the S1368P substitution selected in genotype 1a has an impact on 321 
proteasomal cleavage consistent with altered processing. Therefore, synthetic peptides 25 amino 322 
acids in length either with the prototype sequence (pt) or harboring the S1368P substitution 323 
(S1368P) were digested with constitutive or immune proteasome and the cleavage products were 324 
analyzed by mass spectrometry. In figure 4 the normalized spectral indices for cleavage products 325 
containing the full epitope sequence are shown at different time points after digestion with the 326 
constitutive proteasome (figure 4A) or the immune proteasome (figure 4B). There was no 327 
significant difference in the relative frequency of epitope containing peptides upon digestion of 328 
the prototype or the S1368P variant at any time. In fact, there was a minor trend towards higher 329 
frequencies of epitope containing peptides after 24h when the S1368P variant was digested 330 
(figure 4A and B). As carboxypeptidase activity is basically absent from the endoplasmatic 331 
reticulum (ER), antigen presentation requires peptides with correct C-terminal ends after 332 
proteasomal cleavage (31). We therefore focused the analysis on peptide products ending with 333 
the epitope sequence IPFYGKAI. Figure 4C and D show the normalized spectral indices of 334 
individual peptides after digestion by the constitutive proteaseome (figure 4C) or the immune 335 
proteasome (figure 4D) at different time points. After digestion of the prototype peptide the most 336 
prevalent cleavage product was STTGEIPFYGKAI carrying the residue that was under selection 337 
pressure in HLA-B*51-positive patients in genotype 1a at its N-terminal end (boxed in figure 4C 338 
and D). Also highly prevalent were N-extended peptides with three (TGEIPFYGKAI) or four 339 
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(TTGEIPFYGKAI) additional residues. When the S1368P variant was digested the most 340 
prevalent cleavage product (PTTGEIPFYGKAI) carried the substitution selected in HLA-B*51-341 
positive patients in genotype 1a at its N-terminal end. Importantly, shorter N-extended cleavage 342 
products with three or four additional residues were nearly absent after digestion of the S1368P 343 
variant. Similar results were obtained after digestion by the constitutive proteaseome (figure 4C) 344 
or the immune proteasome (figure 4D). 345 
 346 
The S1368P substitution does not impair viral fitness in HCV genotype 1a 347 
We hypothesized that fitness constraints caused preferred selection of the S1368P substitution in 348 
genotype 1a. To address this experimentally, the recently described genotype 1a full genome 349 
virus TNcc (25) was utilized to study the replication fitness and infectivity associated with the 350 
substitutions S1368P, I1373V or I1380L. 72h after electroporation of virus RNA into Huh-7.5 351 
cells supernatants were used for infection of naïve Huh-7.5 cells (figure 5A). Upon transfection 352 
with the parental HCV TN genome the TCID50 was 1.1 x104 infectious particles per ml. 353 
Approximately the same amount of infectious particles was released upon transfection with the 354 
S1368P variant (0.8 x104 TCID50/ml ) or the I1373V variant (1.3 x104 TCID50/ml ). In contrast, 355 
the I1380L substitution was associated with a decreased TCID50 of 0.2 x104 per ml. The same 356 
hierarchy was observed at the replication level, with only a slight reduction of replication for the 357 
S1368P and I1373V substitution and a 3-fold reduced replication for the I1380L substitution. 358 
This indicates that only the substitution I1380L impairs viral fitness in genotype 1a whereas the 359 
substitutions S1368P and I1380L do not.  360 
 361 
Discussion 362 
Here, we characterized a highly conserved HLA-B*51-restricted CD8+ T cell epitope located in 363 
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the helicase domain of HCV NS3. The high frequency of CD8+ T cells specific for this epitope in 364 
PWID who achieved spontaneous immune control of HCV infection suggests that this CD8+ T 365 
cell response is reproducibly mounted in HLA-B*51-positive patients. Given the high degree of 366 
conservation of the epitope, it was therefore surprising that in chronic infection CD8+ T cell 367 
responses against this epitope were detectable only in PWID infected with genotype 3a and were 368 
completely absent in patients infected with genotype 1a. Although viral sequence polymorphisms 369 
were overall rare, there was selection pressure on the epitope containing region as evidenced by 370 
HLA-B*51-associated viral sequence polymorphisms in all studied genotypes. Notably, in 371 
genotype 1b there was statistical support for selection of escape mutations inside the epitope in 372 
the single-source outbreak, whereas there was only a non-significant trend in the genotype 1b 373 
multi-center cohort. It is possible that escape patterns inside this epitope differ between cohorts. 374 
Alternatively, because the natural sequence variability in this epitope in the genotype 1b multi-375 
center cohort is higher compared with the single-source outbreak, the size of the multi-center 376 
cohort may be too small to unmask an existing effect of HLA-B*51-associated selection pressure.  377 
 378 
The predominant escape mechanisms of substitutions selected by CD8+ T cell immune pressure 379 
in HCV epitopes are impaired binding of the variant epitope to the HLA class I-molecule or 380 
impaired binding of the T cell receptor to the HLA class I/peptide-complex. As an alternative 381 
mechanism, processing of the variant epitope can be affected by substitutions in the epitope 382 
region. We previously reported CD8+ T cell selection of a substitution inside the HLA-B*08-383 
restriced epitope NS3 HSKKKCDEL1395-1403 located in position 9 of the epitope (9). Functional 384 
analyses revealed that the selected leucine to valine or phenylalanine substitution impaired 385 
presentation of the endogenously processed epitope. Similarly, Kimura et al. (32) described 386 
substitutions selected inside targeted CD8+ T cell epitopes that impaired proteasomal processing 387 
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in the chimpanzee model. In contrast, CD8+ T cell selection of substitutions in the epitope 388 
flanking region has not been described yet in HCV. Seifert et al. (33) demonstrated that a tyrosine 389 
to phenylalanine polymorphism located in the C-terminal position +1 of the HLA-A*02-390 
restricted epitope NS3 CVNGVCWTV1073–1081 influenced carboxyterminal cleavage of the 391 
epitope by the proteasome, however, there was no conclusive evidence for immune selection 392 
pressure on this residue (22, 33). In HIV larger population studies of HLA class I-associated viral 393 
adaptation suggested that selection of processing mutations in the epitope flanking region 394 
contributes to mutational immune escape (34). This included substitutions in the C-terminal and 395 
N-terminal epitope flanking regions. Only a few studies directly addressed the functional 396 
consequences of such putative processing mutations (35, 36). The example of selection of altered 397 
processing in HLA-B*51-positive patients infected with HCV genotype 1a supports that similar 398 
immune escape strategies are utilized by HCV. 399 
 400 
Processing and presentation of viral epitopes is a multistep process starting with production of 401 
peptide precursors by proteasomal degradation of viral proteins (reviewed in (37)). These peptide 402 
precursors undergo N-terminal trimming by different endopeptidases and aminopeptidases in the 403 
cytosol and by the aminopeptidases ERAP1 and ERAP2 after the peptides have been transported 404 
by TAP to the ER (38, 39). Importantly, since carboxypeptidase activity is absent from the ER, 405 
production of peptide precursors with correct C-terminal ends by the proteasome is required for 406 
subsequent HLA class I-presentation (31). It has been highlighted that the trimming efficiency of 407 
N-extended epitopes strongly depends on the amino acid composition of the epitope flanking 408 
region. Some amino acids such as leucine, lysine, phenylalanine and methionine are cleaved with 409 
high activity whereas amino acids such as proline and glutamic acid are only poorly cleaved (40). 410 
Accordingly, these latter amino acids are underrepresented in flanking regions of known CD8+ T 411 
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cell epitopes (41). In HCV genotype 1a there was HLA-B*51-associated selection pressure on 412 
position -5 of the epitope with a substitution from serine to proline. Digestion of the N- and C-413 
extended variant peptide by the constitutive and the immune proteasome yielded predominantly 414 
precursor peptides starting with proline, whereas digestion of the prototype yielded also shorter 415 
N-extended precursor peptides. The shorter peptides are advantageous for the transport into the 416 
ER (42), and more importantly, N-terminal trimming of the peptide precursor starting with 417 
proline is inhibited (31). This suggests that the serine to proline substitution altered proteasomal 418 
production of epitope precursors with the consequence of a very low abundance of cleavable N-419 
extended epitopes in the ER, although the latter was not formally tested.  420 
 421 
Selection of CD8+ T cell escape mutations is a trade-off between functional escape and viral 422 
constraints. Indeed, HCV may explore its replication space with different substitutions in targeted 423 
epitopes before some mutations reach fixation (9, 43). The example presented here underlines 424 
that even despite an epitope being conserved across HCV genotypes the selected escape pathways 425 
and the CD8+ T cell response can substantially differ. Although not fully conclusive, our data 426 
suggest that selection of the S1368P substitution represents the optimal trade-off between 427 
functional immune escape and viral fitness in genotype 1a. The I1380L substitution may be 428 
disadvantageous due to its fitness costs despite efficient immune escape. In turn, the degree of 429 
cross-reactivity of the I1373V variant may prevent fixation in genotype 1a despite its low fitness 430 
costs. Interestingly, we observed inter-individual differences in the level of cross-reactivity of the 431 
I1373V substitution with high cross-reactivity in HCV-RNA negative PWIDs and lower levels of 432 
cross-reactivity in PWIDs infected with genotype 3a (figure 1D and E) suggesting that the degree 433 
of cross-reactivity may influence the outcome of infection as previously reported (17). Absence 434 
of the CD8+ T cell response in PWID with chronic genotype 1a infection is unlikely caused by 435 
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lack of priming. The rapid decline of the response in the patient with acute HCV genotype 1a 436 
infection rather suggests secondary failure. This patient harboured a virus with the S1368P 437 
substitution. Although the CD8+ T cell response was clearly impaired against endogenously 438 
processed antigens carrying the S1368P substitution, there was still some degree of T cell 439 
reactivity in our assays. This residual epitope presentation may cause continuous CD8+ T cell 440 
stimulation associated with progressive dysfunction or exhaustion of antigen-specific CD8+ T 441 
cells (44-46) and possibly ultimate extinction of these cells (46).  442 
 443 
The degree of CD8+ T cell reactivity against the S1368P substitution in the context of genotype 444 
1a was comparable to the reactivity against the endogenously processed genotype 3a antigen 445 
suggesting that the epitope is less efficiently processed in the context of genotype 3a. Notably, in 446 
genotype 3a the substitution S1369P also impaired recognition of the endogenously processed 447 
antigen, however, here the I1373V was preferentially selected. One possibility is that in 448 
combination with the lower processing efficiency of the epitope in genotype 3a the I1373V 449 
substitution is sufficient to escape from the immune response. A second plausible explanation is 450 
that the I1373V is associated with lower fitness costs compared to S1369P and I1380L in 451 
genotype 3a. However, this cannot be addressed until robust genotype 3a infectious viruses are 452 
publically available. In either case, at least in some individuals the corresponding CD8+ T cell 453 
response was preserved in our cohort of PWIDs infected with genotype 3a consistent with a 454 
memory T cell phenotype after mutational escape of the targeted antigen as previously reported 455 
(44, 45).  456 
 457 
Taken together, HCV is able to evolutionary adapt to CD8+ T cell immune pressure in multiple 458 
ways. The pathways to mutational escape are predictable but are distinct in different genotypes. 459 
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Beyond selection of mutations inside targeted epitopes that impair HLA class I binding of the 460 
variant peptide ligand or TCR binding to the variant HLA class I/peptide-complex HCV also 461 
inhibits epitope processing by modification of the epitope flanking region under T cell immune 462 
pressure. Importantly, the selected escape pathway of HCV may have consequences for the 463 
destiny of antigen-specific CD8+ T cells. 464 
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Figure legends 639 
Figure 1: CD8+ T cell response against the epitope IPFYGKAI1373-1380 in PWID exposed to 640 
HCV. (A) T cells were expanded for 10 days from PBMCs in the presence of the peptide 641 
IPFYGKAI. After in vitro expansion cells were re-stimulated with the peptide before intracellular 642 
IFN-γ staining. The autologous viral epitope sequences from GT3a infected PWID with 643 
detectable responses are indicated. (B) HLA-B*511373-1380 specific T cells were detected ex vivo 644 
via IPFYGKAI-specific HLA-B*5101 dextramer staining. (C) The HLA-B*511373-1380 specific T 645 
cell response was determined by ELISpot at the indicated time points in a patient with acute HCV 646 
infection. (D&E) Serial peptide dilutions of the prototype (green), I1373V (blue) or I1380L (red) 647 
sequence of the B51-1373 peptide were tested in RNA negative (D) or GT3a infected (E) 648 
patients. Statistical comparisons between groups in (A) and (B) were done with a Kruskal-Wallis 649 
test and significant p-values are indicated. 650 
 651 
Figure 2: Frequency of HLA-B*51-associated viral polymorphisms in the epitope region. 652 
The frequency of variations from the reported prototype sequence of the epitope region in GT1a 653 
(A), GT1b (B), the East-German Anti-D cohort (C) and in GT3a (D) are shown for patients 654 
carrying the HLA-B*51 allele (red) and patients not carrying the HLA-B*51 allele (green). 655 
Positions with significant differences in polymorphism frequencies in the absence and presence 656 
of HLA-B*51 are marked and the p-values (Fisher’s exact test) and the most frequent variant 657 
amino acid are indicated.  658 
 659 
Figure 3: CD8+ T cell response against the endogenously processed epitope IPFYGKAI1373-660 
1380. Effector T cells were expanded for 10 days from PBMCs in the presence of the peptide 661 
IPFYGKAI. HLA-B*51-positive target cells were generated by electroporation with a 662 
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NS3(aa1330-2420)-GFP fusion protein. GFP positive cells were sorted and used as targets for 663 
restimulation of IPFYGKAI-specific effector CD8+ T cells in an effector:target ratio of 1:1 for 4h 664 
followed by an ICS. Mock transfected targets and peptide-pulsed targets served as negative or 665 
positive controls, respectively. (A) Representative FACS results of one ICS. (B) The IFN-γ 666 
response against targets transfected with GT1a prototype NS3 was normalized to 100% and 667 
compared to the response against other targets as indicated. Data represent results from at least 668 
three independent experiments. P-values was calculated using a one sample t test with a 669 
hypothetical value of 100 (S1368P versus pt1a) or an unpaired t test (pt GT3a versus S1369P). 670 
 671 
Figure 4:  Impact of the S1368P substitution on proteasomal degradation. (A and B) The 672 
relative abundance of epitope-containing cleavage products after digestion of 25mer peptides 673 
with the prototype sequence (pt) or carrying the S1368P substitution (S1368P) with (A) 674 
constitutive proteasome or (B) immune proteasome is shown by normalized spectral indices. (C 675 
and D) The relative abundance of cleavage products with the correct C-terminal epitope end is 676 
shown by normalized spectral indices of individual peptides after digestion with (C) constitutive 677 
proteasome or (D) immune proteasome.  678 
 679 
Figure 5: Infectivity and Replication of wild type and mutant TNcc strains. RNA transcripts 680 
of the parental HCV TN genome and TN mutants were transfected into Huh-7.5 cells. (A) 681 
Seventy-two hours later, cell-free supernatant was used for inoculation of naïve Huh-7.5 cells. 682 
The TCID50 of the variants was determined by a limiting dilution assay and staining with Core 683 
and NS5A-specific antibodies. (B) RNA levels 72h post-transfection were measured by 684 
quantitative real-time RT-PCR. The RNA levels in presence of 2’Methyladenosin (2’CMA) was 685 
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used for normalization. The ratio of measured HCV RNA to measured RNA levels in presence of 686 
2’CMA was calculated for each construct. Data from four independent experiments are shown.   687 
 688 





Table 1: Patient characteristics 
                                   
ID Genotype viral load  IU/ml A L S T T G E I P F Y G K A I P 
a 
138 1a 2148000 . . . . . . . . . . . . . . . . 
154 1a 777200 . . . . . . . . . . . . . . . . 
175 1a 2200000 . . P . . . . . . . . . . . . . 
251 1a 61790 not done
278 1a 3015000 . . . . . . . V . . . . . . . . 
283 1a 2422000 . . . . . . . . . . . . . . . . 
299 1a 275700 . . . . . . . . . . . . . . . . 
324 1a 2469000 . . . . . . . . . . . . . . . . 
348 1a 83080 . . . . . . . . . . . . . . . .   
393 1a 5282000 not done
408 1a 1562000 . . . . . . . . . . . . . . . . 
423 1a 320900 not done
581 1a 3942000 not done
084 1b 61550 . . . N I . . . . . . . . . . . 
117 1b 1033000 . . . N I . . V . . . . . . . . 
332 1b 220000 . . . N . . . . . . . . . . . . 
096 3a 247700 . . G S E . . . . . . . . . . . 
113 3a 2258000 . . G S E . . . . . . . . . . . 
122 3a 87400 . . G S E . . . . . . . . . . . 
137 3a 1046000 . . G S E . . . . . . . . . . . 
176 3a 924700 . . G S E . . . . . . . . . . . 
206 3a 368000 . . G S E . . . . . . . . . L . 
240 3a 154500 . . G S E . . . . . . . . . . . 
257 3a 3642 not done
274 3a 146300 . . G S E . . V . . . . . . . . 
292 3a 80690 not done
466 3a 34010000 . . G S E . . . . . . . . . . . 
533 3a 511500 . . G S D . . . . . . . R . . . 
042 RNA neg - 
062 RNA neg - 
110 RNA neg - 
161 RNA neg - 
196 RNA neg - 
242 RNA neg - 
264 RNA neg - 
286 RNA neg - 
344 RNA neg - 
365 RNA neg - 
417 RNA neg - 
418 RNA neg - 
474 RNA neg - 
574 RNA neg - 
587 RNA neg - 
a H77 prototype sequence 
 
